Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation
Cell Chemical Biology · 2025-06 · 32 (6) · 839-853.e6
DOI: 10.1016/j.chembiol.2025.05.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Chemical Biology, 2025-06. Verfasst von Marta Baro und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06510, USA. Electronic address: marta.baro@yale.edu. Hauptthemen laut MEDLINE: Hexosyltransferases, Membrane Proteins, Antineoplastic Agents, Enzyme Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Protein asparagine (N)-glycosylation, which promotes the folding and trafficking of cell surface receptors, has not traditionally been viewed as a viable target in oncology due to the essential and non-redundant enzymatic activities required for glycan synthesis and transfer. However, in mammals, an exception is the presence of the oligosaccharyltransferase (OST) catalytic subunit paralogs, STT3A and STT3B. In this study, we investigate the biological activity of OST inhibitors and develop a strategy for selectively inhibiting N-glycosylation that is optimized for its downstream effects on the EGFR glycoprotein. Small molecules with improved pharmacokinetic properties and selective preferences for STT3A or STT3B were synthesized, characterized in vitro, and advanced to in vivo testing. The lead compound from this series, NGI-189, induces tumor regression or growth delay in patient-derived and TKI-resistant EGFR-mutant lung cancer xenografts without causing toxicity. Collectively, these findings suggest that bioavailable OST inhibitors can be developed as therapeutic agents for oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06510, USA. Electronic address: marta.baro@yale.edu.
- Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06510, USA.
- Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06510, USA; Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510, USA.
- New England Discovery Partners, Branford, CT 06405, USA.
- Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06510, USA; Department of Biology, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.
- Department of Internal Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, CT 06510, USA.
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Baro, M., Lee, H., Kelley, V., Lou, R., Phoomak, C., Politi, K., Zeiss, C. J., Van Zandt, M., & Contessa, J. N. (2025). Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation. Cell Chemical Biology, 32(6), 839-853.e6. https://doi.org/10.1016/j.chembiol.2025.05.005
Vancouver
Baro M, Lee H, Kelley V, Lou R, Phoomak C, Politi K, et al. Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation. Cell Chemical Biology. 2025;32(6):839-853.e6. doi:10.1016/j.chembiol.2025.05.005
BibTeX
@article{Baro2025,
author = {Baro, Marta and Lee, Hojin and Kelley, Vanessa and Lou, Rongliang and Phoomak, Chatchai and Politi, Katerina and Zeiss, Caroline J and Van Zandt, Michael and Contessa, Joseph N},
title = {Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation},
journal = {Cell Chemical Biology},
year = {2025},
volume = {32},
number = {6},
pages = {839--853.e6},
doi = {10.1016/j.chembiol.2025.05.005}
}
EUVIMED